We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based biotechnology firm Engitix has signed a licensing and collaboration agreement with Takeda Pharmaceutical for the discovery and development of new drugs to treat fibrotic liver diseases.
Takeda has signed a licensing agreement with UK biotech Engitix to develop new therapies for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).